Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability

Kurniawan, Juferdy; Gani, Rino Alvani; Hasan, Irsan; Sulaiman, Andri Sanityoso; Lesmana, Cosmas Rinaldi Adithya; Jasirwan, Chyntia Olivia Maurine; Kalista, Kemal Fariz; Nababan, Saut Horas Hatoguan; Zulkifly, Steven

doi:10.1007/s12664-018-0921-2

Cited by 8 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anemia was shown to be the most common consequence linked with antiviral medication, according to our findings. In comparison to earlier studies undertaken to establish the efficacy of Antiviral Therapy in HCV infected patients, which found a prevalence of anaemia ranging from 18 to 30% [19][20], these findings are consistent.…”

Section: Discussionsupporting

confidence: 85%

Efficacy of Combination Therapy Sofosbuvir, Daclatasvir and Ribavirin in Patients of Hepatitis C

Quddus¹,

Zaib²,

Munawar³

et al. 2021

PJMHS

View full text Add to dashboard Cite

Aim: To determine the effectiveness of antiviral drugs such as sofosbuvir, daclatasvir and ribavirin in hepatitis C patients and frequency of complications associated to antiviral therapy. Study Design: Prospective study. Place and Duration: This study was conducted at the department of Gastroenterology and General Medicine AK CMH / Sheikh Khalifa bin Zaid Al Nahyan Hospital Rawalakot Azad Kashmir for one year duration from 5th July 2020 to 5th July 2021. Methodology: 150 patients of both genders presented with hepatitis C were included. Patient’s ages were ranging from 25 to 70 years. After taking informed consent from all the patients, detailed medical history including age, sex, residence and education were recorded. Quantitative PCR test was obtained before starting the antiviral therapy, kit method was used. Treatment response was examined after completion of therapy. All the statistical data was analyzed by SPSS 24.0. Results: 88 (58.67%) patients were males while 62 (41.33%) patients were females. Mean age of patients was 48.52±9.38 years. At the end of treatment, 132 (88%) patients were cured and 15 (10%) patients were not cured, 3 (2%) patients had lost to follow-up. Complications associated to therapy were noted as anemia, ascites, hepatic encephalopathy and liver cirrhosis in 40 (26.67%), 20 (13.33%), 7 (4.67%) and 6 (4%) patients respectively. Conclusion: Combination antiviral therapy with Sofosbuvir, daclatasvir and ribavirin shows better results in patients with Hepatitis C with 88% cure rate. Anemia was the most frequent complication found at end of therapy. Keywords: Hepatitis C, Sofosbuvir, Daclatasvir, Ribavirin

show abstract

Section: Discussionsupporting

confidence: 85%

Efficacy of Combination Therapy Sofosbuvir, Daclatasvir and Ribavirin in Patients of Hepatitis C

Quddus¹,

Zaib²,

Munawar³

et al. 2021

PJMHS

View full text Add to dashboard Cite

show abstract

“…This study did not use VEL, but our results with use of all of the four aforementioned treatment protocols were in line with previous data. 12,13 In a study by Umar et al SVR was achieved in 83%. 14 In 2018, a study by Abozeid M et al showed SVR achieved in 98%.…”

Section: Discussionmentioning

confidence: 96%

“…This study did not use VEL, but our results with use of all of the four aforementioned treatment protocols were in line with previous data. 12 , 13 …”

Section: Discussionmentioning

confidence: 99%

Effectiveness of Sofosbuvir and Daclatasvir in treatment of Hepatitis-C: An experience of tertiary care hospital in Karachi

Butt¹,

Saleem

Khan³

et al. 2021

Pak J Med Sci

View full text Add to dashboard Cite

Objective: To assess the effectiveness of Sofosbuvir (SOF) and Daclatasvir (DCV) in patients with chronic hepatitis C (CHC), compensated cirrhosis (CC) and decompensated cirrhosis (DCLD) either treatment naïve or experienced. Methods: This was a prospective, observational study, conducted from January 2017 to December 2018 at Jinnah Postgraduate Medical Centre, Karachi. All patients above 12 years of age with detectable HCV RNA PCR were included. Patients were divided into three groups: CHC, CC and DCLD. SOF and DCV for 12 or 24 weeks were given. Ribavirin (RBV) was given to treatment experienced and cirrhotic patients. Primary outcome was End of Treatment Response (ETR) and secondary outcome was Sustained Virological Response (SVR) at post treatment week 12 or 24. Results: Total 300 patients with mean age of 40.49 ± 13.86 were enrolled. Majority were females 174 (58%). CHC were 200 (66.6%) while cirrhotic were 100 (33.4%). Treatment naïve patients were 267 (89%) and 33 (11%) patients were experienced. Most common genotype was 3 (83%). ETR was achieved in 292 (97.33%) and SVR in 265 (88.33%) patients respectively. Conclusion: SOF plus DCV with or without RBV is a highly effective treatment for chronic HCV and is still used in many centers of Pakistan. This regimen has excellent results for GT-3. The outcomes are mainly influenced by the presence or absence of cirrhosis. doi: https://doi.org/10.12669/pjms.37.7.4627 How to cite this:Butt N, Anoshia, Khan MA, Akbar A. Effectiveness of Sofosbuvir and Daclatasvir in treatment of Hepatitis-C: An experience of tertiary care hospital in Karachi. Pak J Med Sci. 2021;37(7):2014-2019. doi: https://doi.org/10.12669/pjms.37.7.4627 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

“…This regimen is obviously burdened with fewer side effects, but the optimal duration of treatment in GT2 is still object of debate. [16][17][18] An important further consideration is that the reported percentage of cirrhotic subjects in the aforementioned studies was quite modest (between 20% and 30%), 10,[13][14][15][16][17][18] like almost all the previous ones, starting from clinical trials. [19][20][21][22] So, in our opinion, the current literature is still not conclusive for the very specific subset of cirrhotic GT2 patients in defining the optimal RBV dose and the correct therapy duration, the latter one concerning specifically SOF plus RBV treatment, for which Italian (and European) clinicians could lawfully-in accordance with the guidelines available at that time-administer four different treatment schedules, namely 12, 16, 20, or 24 weeks.…”

Section: Introductionmentioning

confidence: 93%

“…However, taking into consideration that anemia can represent a relevant problem especially for the most frail categories of subjects and that there are patients who are not eligible for RBV mostly due to baseline anemia, an alternative strategy to reducing RBV on treatment is represented by RBV‐free DAA regimens, the first of which historically available was the association of SOF plus the NS5A inhibitor daclatasvir (DCV). This regimen is obviously burdened with fewer side effects, but the optimal duration of treatment in GT2 is still object of debate 16–18 …”

Section: Introductionmentioning

confidence: 99%

Sofosbuvir‐based therapies in genotype 2 hepatitis C virus cirrhosis: A real‐life experience with focus on ribavirin dose

Smirne

D’Avolio

Bellan

et al. 2021

Pharmacology Res & Perspec

View full text Add to dashboard Cite

show abstract

Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability

Cited by 8 publications

References 12 publications

Efficacy of Combination Therapy Sofosbuvir, Daclatasvir and Ribavirin in Patients of Hepatitis C

Efficacy of Combination Therapy Sofosbuvir, Daclatasvir and Ribavirin in Patients of Hepatitis C

Effectiveness of Sofosbuvir and Daclatasvir in treatment of Hepatitis-C: An experience of tertiary care hospital in Karachi

Sofosbuvir‐based therapies in genotype 2 hepatitis C virus cirrhosis: A real‐life experience with focus on ribavirin dose

Contact Info

Product

Resources

About